Gastrointestinal Cancer

S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

Experts review ongoing clinical research with JAK inhibitors in advanced pancreatic cancer as well as some strategies for preclinical testing of vertical inhibition of the JAK pathway.

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

Germline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.

Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.

Andrew Hendifar, MD, discusses how PEGPH20 improved progression-free survival by 4.9 months in patients with advanced pancreatic cancer with high expression levels of hyaluronan.

Yung-Jue Bang, MD, PhD, discusses how the results of the KEYNOTE-012 study demonstrate the potential of immunotherapy in treating gastric cancer.

Pierre M. Gholam, MD, discusses managing elderly patients with advanced HCC, including current practices and emerging strategies.